Semaglutide

What is Semaglutide?

Semaglutide is a GLP-1 receptor agonist developed by Novo Nordisk and FDA-approved in 2021 (Wegovy) for chronic weight management. It activates glucagon-like peptide-1 receptors to mimic natural satiety hormones, delivering 15% average body weight reduction with one of the most extensive clinical safety databases among peptides. Available as once-weekly injection with proven long-term tolerability.

Main Effects

• 15% average body weight reduction in clinical trials
• Sustained appetite suppression through GLP-1 activation
• Improved blood glucose control and insulin sensitivity
• Reduced cardiovascular risk factors (blood pressure, lipid profile)
• Slower gastric emptying for prolonged satiety
• Anti-inflammatory effects on metabolic tissues
• Excellent long-term safety profile with years of clinical data
• Maintained results with consistent dosing

Usage Guidelines

Reconstitution

For a 1mg vial: Inject 1mL bacteriostatic water slowly. Gently roll to dissolve; do not shake vigorously. Creates 1mg/mL concentration. Reconstituted solution stable 28 days refrigerated.

Example Protocol

• Week 1-4: 0.25mg once weekly (subcutaneous, preferably Thursday)
• Week 5-8: 0.5mg once weekly
• Week 9-12: 1mg once weekly
• Week 13+: 1.7-2.4mg once weekly (based on response)

Slower escalation than Tirzepatide but improves tolerability. Most users effectively reach plateau at 1.7mg for sustained results. Inject abdomen, thigh, or upper arm. Cycle 12-20 weeks. No tapering needed.

Stacking / Combinations

• With DSIP: Improve sleep quality and nocturnal HGH release; 100-300mcg before bed
• With B12: Enhance energy and mood during appetite suppression; 500-1000mcg weekly
• With GHK-Cu: Maintain skin quality during weight loss; topical application daily

Precautions

• Contraindication: History of thyroid medullary carcinoma or MEN2 syndrome
• Monitor for pancreatitis (severe abdominal pain indicates emergency)
• Not safe during pregnancy; discuss nursing compatibility
• Risk of dehydration; maintain water intake (2-3L daily minimum)
• May reduce effectiveness of oral medications due to delayed gastric emptying

Possible Side Effects

• Common (weeks 1-4): Mild nausea (typically transient), appetite reduction (therapeutic), constipation
• Occasional: Vomiting, diarrhea, headaches, mild fatigue
• Rare: Gallbladder issues, pancreatitis, severe allergic reaction
• Slower titration significantly reduces side effect severity

Storage

Reconstituted: 2-8°C (refrigerated), light-protected, 28-day stability. Lyophilized vials: Room temperature, avoid direct sunlight. Do not freeze reconstituted solution.

Mechanism of Action

Semaglutide is a 97-amino acid GLP-1 receptor agonist (96% homology to endogenous GLP-1):

Central Appetite Suppression: Crosses blood-brain hypothalamus barrier to directly suppress hunger centers in the lateral hypothalamus while activating satiety centers in the ventromedial nucleus.

Pancreatic Beta Cell Stimulation: Glucose-dependent insulin secretion increasing with meal intake, preventing hypoglycemia during fasting.

Gastric Emptying Slowing: Delays stomach-to-intestine food transit, extending postprandial satiety.

Systemic Effects: Anti-inflammatory action on adipose tissue; improved insulin sensitivity at skeletal muscle and liver.

Result: Sustained appetite suppression with excellent metabolic safety profile.

FAQ

Q: Why is Semaglutide cheaper than Tirzepatide?

A: Tirzepatide is dual-pathway (stronger effect); Semaglutide is single-pathway. Both are effective; Semaglutide has longer clinical track record (8+ years vs. 3 years). Price reflects mechanism, not efficacy.

Q: Can I switch from Tirzepatide to Semaglutide?

A: Yes, but taper Tirzepatide over 1 week and allow 1-week washout before starting Semaglutide to avoid stacking effects.

Q: Does Semaglutide affect muscle mass?

A: Less muscle loss than diet alone due to preserved protein synthesis, but resistance training is critical to maintain lean mass during 15% weight loss.

Q: How long should I use it?

A: Effective for 12-18 month cycles. Post-cycle, maintain with diet/exercise; most users can sustain 50-70% of weight loss with lifestyle changes.

Q: Can I use Semaglutide year-round?

A: Safe for long-term use; clinical trials show sustained benefit at 2+ years. Typically dose at 1.7-2.4mg weekly indefinitely if needed.